CRISPR-Cas9 drugmakers like Vertex should come to the table early, says ToolGen’s IP chief
Chief Legal Officer Yoori Kim argues that current patent uncertainty should fuel rather than thwart licensing deals
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Register now
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.
Subscribe now